Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO
2024

   Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1
   Agonist at BIO 2024
   New York, 05/16/2024 / 09:00, EST/EDT - EQS Newswire - Laxxon
   Medical

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Laxxon Medical, a US-based
pharma-technology company pioneering a new generation of advanced
pharmaceuticals through novel 3D screen-printing platform technology SPID�,
announced today its participation in the 2024 BIO International Convention
on June 3-6, 2024 in San Diego, CA. The Company will be showcasing its LXM.2
asset to potential partners.

The BIO International Convention is the world's largest biotech partnering
and education event, attracting 20,000+ biotechnology and pharma leaders for
a week of intensive networking to discover new opportunities and
partnerships.

LXM.2 is a non-invasive, once-a-day 3D Printed oral GLP-1 Agonist treatment
for weight loss. Using the proprietary 3D printing manufacturing process
SPID�, the company has combined the GLP-1 agonist with a permeation enhancer
to increase bioavailability. Laxxon will utilize the 505(b)2 pathway to
accelerate its development program. The Company will be seeking
out-licensing or co-development opportunities for LXM.2.

About Laxxon Medical

Laxxon Medical is a leading pharma-technology company pioneering a new
generation of advanced pharmaceuticals through SPID�-Technology, a 3D
screen-printing platform technology which unlocks innovative drug delivery
advancements paired with fast-tracked market access and extensive IP
protection to yield disruptive opportunities for the pharmaceutical industry
and its patients.

With SPID�, Laxxon can develop and manufacture advanced versions of new and
existing pharmaceutical drugs while extending and adding new patent
protection through the technology transfer process. Laxxon can fully utilize
the FDA's 505b(2) regulatory pathway in the US and Hybrid applications under
article 10(3) of Directive 2001/83/EC in the EUR, which fast tracks product
routes to market, and Laxxon's robust and growing IP protects any Company
asset until at least 2037.

Laxxon's pipeline includes ongoing working-projects with notable pharma
players, biotech companies and research universities, in addition to 13
in-house Advanced Patented Generics products. Laxxon's IP is continuously
growing and consists of 150 patents and patent applications with more than
3,000 patent claims.

For more information, please visit www.laxxonmedical.com or contact:
Frances Hoggard | Communications Manager | frances.hoggard@laxxonmedical.com

SOURCE: Laxxon Medical


05/16/2024 EQS Newswire / EQS Group AG